Randomized Clinical Trials With Biomarkers: Design Issues
Top Cited Papers
Open Access
- 14 January 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 102 (3), 152-160
- https://doi.org/10.1093/jnci/djp477
Abstract
Clinical biomarker tests that aid in making treatment decisions will play an important role in achieving personalized medicine for cancer patients. Definitive evaluation of the clinical utility of these biomarkers requires conducting large randomized clinical trials (RCTs). Efficient RCT design is therefore crucial for timely introduction of these medical advances into clinical practice, and a variety of designs have been proposed for this purpose. To guide design and interpretation of RCTs evaluating biomarkers, we present an in-depth comparison of advantages and disadvantages of the commonly used designs. Key aspects of the discussion include efficiency comparisons and special interim monitoring issues that arise because of the complexity of these RCTs. Important ongoing and completed trials are used as examples. We conclude that, in most settings, randomized biomarker-stratified designs (ie, designs that use the biomarker to guide analysis but not treatment assignment) should be used to obtain a rigorous assessment of biomarker clinical utility.Keywords
This publication has 23 references indexed in Scilit:
- Clinical Trial Designs for Predictive Biomarker Validation: Theoretical Considerations and Practical ChallengesJournal of Clinical Oncology, 2009
- Monitoring for Lack of Benefit: A Critical Component of a Randomized Clinical TrialJournal of Clinical Oncology, 2009
- Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trialThe Lancet, 2008
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal CancerThe New England Journal of Medicine, 2008
- A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancerAnti-Cancer Drugs, 2007
- Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2007
- Clinical trials design and treatment tailoring: General principles applied to breast cancer researchCritical Reviews in Oncology/Hematology, 2006
- Clinical trial design for microarray predictive marker discovery and assessmentAnnals of Oncology, 2004
- Evaluating the Efficiency of Targeted Designs for Randomized Clinical TrialsClinical Cancer Research, 2004
- The roles of FLT3 in hematopoiesis and leukemiaBlood, 2002